secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001193125-25-113275
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra reproxalap meets primary endpoint in Phase 3 dry eye chamber trial; NDA resubmission planned mid-2025
--------------------------------------------------------------------------------

- Reproxalap statistically superior to vehicle on ocular discomfort (LS mean diff -6.5, P=0.002) in Phase 3 chamber trial (n=58 per arm).
- No notable baseline differences across treatment arms; Aldeyra believes data address FDA CRL from April 2025.
- NDA resubmission anticipated mid-2025 pending Type A meeting; review expected six months.
- A recent field trial was numerically supportive but did not reach statistical significance; will be submitted as supportive.
- No safety signals or treatment-related discontinuations; reproxalap well tolerated in over 2,900 patients studied.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/0001193125-25-113275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/d941544d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-113275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer